The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

RPT-ANALYSIS-Buy yen in crisis? Not this year

Wed, 25th Jul 2018 07:00

* Yen weakest G10 currency this month despite globalturbulence

* Investors doubt BOJ can reduce stimulus aggressively

* Japanese purchases of foreign equities highest in nearly 3years

* Bond investors growing reluctant to hedge foreign holdings

* Japanese firms spend record sum on foreign acquisitions inH1

By Tom Finn and Hideyuki Sano

LONDON/TOKYO, July 24 (Reuters) - The trade is familiar toinvestors worldwide: in times of turmoil, rush for cover bybuying the Japanese yen.

This year a global trade row has erupted, Donald Trump haslamented the dollar's strength - ignoring a custom that U.S.presidents avoid openly interfering in financial markets - andthe Chinese yuan has tumbled.

And yet the yen has stayed resolutely weak, becoming theweakest of the G10 developed market currencies this month.

The yen's safe-haven status is not in doubt, underpinned byJapan's nearly two trillion yen ($18 billion) monthly tradesurplus. But without a massive world market shock to discourageJapanese investors from buying foreign assets, the yen is likelyto stay weak - above all because the Bank of Japan lags behindits central bank peers in ending monetary stimulus.

Investors doubt the BOJ can aggressively reduce the stimulusmeasures as inflation remains well below target and corporateprofits are recovering slowly.

The BOJ is debating policy changes to make its stimulus"more sustainable", sources told Reuters, but this pushed theyen up only briefly on Monday.

"The Bank of Japan is still pursuing easing which is stillprompting domestic investors to borrow yen and buy overseasassets," said Anton Eser, CIO at Legal and General InvestmentManagement which manages 983 billion pounds ($1.29 trillion) inassets.

While U.S. interest rates have risen seven times since 2016and the European Central Bank plans to wind down its bondpurchases by end-2018, the BOJ is still buying local securities,albeit at a slower pace.

Japanese investors are therefore likely to keep pouringmoney into foreign assets, despite global market wobbles.

Their net purchases of foreign equities reached 1.5 trillionyen in June, the highest in nearly three years. Even as thetrade row deepened, they bought 371 billion yen of overseasstocks during the first week of July.

HEDGE TRIMMING

However, Japanese funds are growing reluctant to hedgeexposure to billions of dollars' of U.S. assets.

"I suspect some investors are reducing currency hedge ontheir foreign bond investments," a senior trader at a majorJapanese bank in Tokyo told Reuters, requesting anonymity.

Japanese fund managers buying 10-year U.S. Treasuries on afully hedged basis now earn a slim 33 basis points in yield,compared with 50-80 bps last year. As the Federal Reserve keepsraising interest rates, even that yield advantage could vanish.

And a lack of demand for yen from investors in the currencyforwards market would feed into falling spot market demand.

"Currency hedging costs have risen rapidly. Japaneseinvestors have stopped hedging. That stops them buying the yen.The flow is for selling yen," said Adam Cole, chief currencystrategist at RBC in London.

Another source of yen selling is Japanese companies makingacquisitions overseas due to lacklustre economic growth and ashrinking population at home. Thomson Reuters data showsJapanese investors spent a record 13.0 trillion yen on foreignacquisitions in the first half of the year.

These included Takeda Pharmaceutical's $62 billionacquisition of London-listed drugmaker Shire Plc.

Initially the deal helped to push the British pound up morethan four percent against the yen in early-April, but in Maytraders started to buy dollars on news that Takeda's payment toShire shareholders would be in dollars.

TRADE WINDS

Trade conflict would seem yen-positive by raising globalmarket volatility. In fact, this is helping to push it down.

Japan is vulnerable to a trade war. Autos, for instance,comprise almost 30 percent of its exports to the United Statesand new U.S. tariffs could hurt Tokyo's vaunted trade surplus.

Also, as fund managers worldwide cut foreign investmentholdings, much of this cash is going to U.S. markets instead ofthe "safe havens". The dollar is likely to benefit from a tradewar due to the United States' lower reliance on exports.

"Rather than move into the Swiss franc or the Japanese yen,the widening interest rate differential in favour of the U.S.dollar is currently providing investors with a strongalternative," Rabobank currency strategist Jane Foley said.

Global investors now hold their biggest overweight positionin U.S. equities in 17 months, Bank of America Merrill Lynch'spoll showed last week. Other equity holdings have fallen andallocations to Japan slid for the third time in four months.

Correlation has been high this year between Japanese stocksand the yen, with both losing ground, BAML's FX strategist KamalSharma noted. That's unusual because yen weakness usually booststhe Nikkei average.

"If U.S. share markets crumbled, then we would be in adifferent situation," the Tokyo-based trader said. "But as longas Wall Street is in the risk-on mode, the dollar will besupported against the yen."($1 = 111.2400 yen)($1 = 0.7629 pounds)

(Additional reporting by Shinji Kitamura and Tommy Wilkes;Graphic by Ritvik Carvalho; Writing by Saikat Chatterjee;Editing by Sujata Rao and David Stamp)

More News
14 Sep 2018 09:15

Shire gains as takeover approved by China

(Sharecast News) - Japan's Takeda Pharmaceutical has received regulatory approval from China for its $62bn takeover of London-listed Shire.

Read more
13 Sep 2018 10:56

Takada eyeing potential Shire asset sales to pay down debt

(Sharecast News) - Takeda Pharmaceutical may try and sell Shire's dry-eye drug once it completes the $62bn takeover purchase of the UK-listed biotech, according to a report on Thursday.

Read more
13 Sep 2018 08:25

Takeda weighs sale of Shire's eye care business to cut debt- Bloomberg

Sept 13 (Reuters) - Japan's Takeda Pharmaceutical is considering selling Shire Plc's eye care business once it closes its $62 billion purchase of the London-listed drugmaker, as it looks a

Read more
12 Sep 2018 16:12

Takeda to pack up Illinois HQ, nearly 1,000 workers to be affected

Sept 12 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd said on Wednesday it plans to shut its U.S. headquarters in Deerfield, Illinois and move it to the greater Boston area, following the —

Read more
12 Sep 2018 07:22

Shire gets EC marketing authorisation for 'VEYVONDI' treatment

(Sharecast News) - Rare diseases specialist Shire announced on Wednesday that the European Commission has granted marketing authorisation for 'VEYVONDI', for the treatment of bleeding events and the treatment and prevention of surgical bleeding in adults with von Willebrand disease, when desmopressin treatment alone is ineffective or not indicated.

Read more
10 Sep 2018 16:08

Two Shire Subsidiaries Receive Majority Early Offers For Senior Notes

LONDON (Alliance News) - Biotechnology company Shire PLC on Monday said two of its subsidiaries, Baxalta Inc and Shire Acquisitions Investments Ireland DAC, had received early offers for a of the

Read more
7 Sep 2018 09:33

BROKER RATINGS SUMMARY: Goldman Cuts Burberry; Redburn Cuts HSBC

LONDON (Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:----------FTSE 100----------GOLDMAN CUTS GROUP TO BUY -

Read more
6 Sep 2018 11:20

European Shares Reverse Early Losses On Improving Sentiment

BRUSSELS/FRANKFURT/PARIS (Alliance News) - European stocks were marginally higher on Thursday after having fallen to a five-month low earlier in the day.Sentiment improved somewhat after US

Read more
6 Sep 2018 10:54

TOP NEWS: Shire Buys Swiss Plasma Collection Firm Sanaplasma

LONDON (Alliance News) - Shire PLC said Thursday it has bought Swiss source plasma collection company sanaplasma AG for an undisclosed sum.The FTSE 100 pharmaceutical giant said that the is

Read more
6 Sep 2018 10:52

Shire buys Swiss plasma firm sanaplasma for undisclosed sum

(Sharecast News) - Pharmaceuticals giant Shire on Thursday said it had bought Switzerland's sanaplasma AG for an undisclosed sum.

Read more
6 Sep 2018 07:48

UPDATE 1-UK Stocks-Factors to watch on Sept. 6

Sept 6 (Reuters) - Britain's FTSE 100 futures were down 0.1 percent ahead of the cash market open on Thursday. * DIXONS CARPHONE: Dixons Carphone, the troubled British electricals and a

Read more
31 Aug 2018 10:16

Shire Completes USD2.4 Billion Oncology Franchise Sale To Servier

LONDON (Alliance News) - Irish biotechnology giant Shire PLC said Friday it has completed the sale of its oncology franchise to Servier SAS.The FTSE 100-listed company sold its franchise, a

Read more
31 Aug 2018 09:07

Shire completes $2.4bn oncology sale to Servier

(Sharecast News) - Shire has completed the sale of its oncology franchise to Servier for $2.4bn, it announced on Friday.

Read more
24 Aug 2018 14:04

TOP NEWS: Shire Launches Tender Offer To Buy Up To USD2 Billion Notes (ALLISS)

LONDON (Alliance News) - Biotechnology company Shire PLC on Friday said its wholly-owned subsidiaries Baxalta and Shire Acquisitions Investments Ireland DAC launched a tender offer to repurchase a

Read more
24 Aug 2018 13:54

MARKET ANALYSIS: Futures Pointing To Initial Strength On Wall Street

WASHINGTON (Alliance News) - The major US index futures are pointing to a higher opening on Friday, with stocks likely to move to the upside after ending the previous session modestly upward on a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.